Los Angeles Registration
The Los Angeles Area
March 27, 2010
7:00 am to 4:30 pm
The Los Angeles Downtown Marriott
333 S. Figueroa Street
Los Angeles, CA 90071
Click here to register
Group Discounts Available! To register a group, please call a PLN registration coordinator at 609-371-1137. |
Agenda
7:00 am–8:00 am |
Buffet Breakfast |
 |
 |
Cosponsored by North American Center for Continuing Medical Education, LLC and the University of Kentucky College of Pharmacy
The University of Kentucky is an Equal Opportunity University
Target Audience
This activity is designed for health-system pharmacists.
Activity Overview
The interactive educational conference will occur in the Grand Ballroom of the Los Angeles Downtown Marriott on Saturday, March 27, 2010 from 7:00 am to 4:30 pm. A question-and-answer session with the faculty will follow each of the 7 sessions.
Participants will obtain an activity folder, including lecture slides and evaluation completion instructions, onsite before the conference. Participants will be asked to complete all conference evaluations online following the conclusion of the conference. Each 1 hour session requires completion of a unique evaluation for receipt of credit.
All online evaluations will be available following the conference, and will remain active for 2 weeks following the live event at www.naccme.com/PLN. Participants will be required to register for an account (existing users can sign into an existing account) with naccme.com. PLEASE NOTE: Registration for the Pharmacy Learning Network conference does not constitute account creation on naccme.com.
In order to access each of the 7 session evaluations, participants will be required to enter the email address provided upon registration for the PLN conference after logging in to naccme.com. Each evaluation must be completed in order to immediately print documentation of credit for that session.
All individuals who participate in the conference and complete and submit the evaluation form online by April 10, 2010 may immediately print their documentation of credit.
Note: Participants are eligible to receive up to 7 contact hours of continuing education credit. Participants are only eligible for credit for those sessions attended in full.
Hardware/Software Requirements
All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape, or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.
Registration Fee
Early-Bird Discount Registration Fee: $45
Regular Registration Fee: $55
Group Early-Bird Rate: $35 per person
Regular Group Rate: $45 per person
(all registrations must be received at the same time either via mail, fax, or phone. Group discounts are not available online)
For questions regarding this educational activity, please contact Kristin Dickie at 609-371-1137.
Refund Policy
Full refunds will be given until March 13, 2010. To receive a refund, contact PLN at 609-371-1137.
CPE Accreditation
The University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
These knowledge-based activities have been assigned UAN 022-999-10-004-L01-P, 022-999-10-005-L01-P, 022-999-10-006-L01-P, 022-999-10-007-L05-P, 022-999-10-008-L01-P, 022-999-10-009-L01-P, 022-999-10-010-L01-P and will award up to 1 contact hour (0.1 CEU) of continuing pharmacy education credit per activity in states that recognize ACPE providers.
Statements of credit will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes signing in at registration, attending the entire session for which credit is claimed, completing the activity evaluation and requesting credit online at conclusion of the activity. The College complies with the Accreditation Standards for Continuing Pharmacy Education.
ADA Statement
The University of Kentucky College of Pharmacy and the North American Center for Continuing Medical Education comply with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Kristen Jassin at 609-371-1137.
ANTICOAGULATION
Improving Adherence to VTE Prophylaxis Guidelines and Measures: Opportunities for Health-System Pharmacists to Make a Clinical and Economic Impact
| Chair | Presenter |
Paul P. Dobesh, PharmD, FCCP, BCPS |
Ann Wittkowsky, PharmD |
Learning Objectives
- Stratify patients based on venous thromboembolism (VTE) risk and outline appropriate prophylaxis
- Promote adherence to VTE prophylaxis guidelines and measures
- Employ best practices for VTE prophylaxis in special patient populations
- Assist in ensuring the continuity of VTE care through the development and implementation of discharge protocols
UAN 022-999-10-004-L01-P
HEMOSTASIS
Effective Strategies for Reaching Hemostasis in Surgical Patients: The Pharmacy Role in Minimizing Morbidity and Costs
| Chair | Presenter |
Bradley A. Boucher, PharmD, |
Mark A. Malesker, PharmD |
Learning Objectives
- Quantify the impact of transfusions on hospital costs and clinical outcomes
- Outline the safety and efficacy profiles and pharmacoeconomics of available topical and biologic hemostatic agents
- Utilize available resources to achieve hemostasis, improve safety, and reduce morbidity and hospital costs through best practices in monitoring and pharmacologic strategies
UAN 022-999-10-005-L01-P
INFECTION CONTROL
MRSA: Understanding Institutional Resistance Patterns and Implementing Methods for Improved Outcomes
| Chair | Presenters |
Robert P. Rapp, PharmD |
David P. Nicolau, PharmD, FCCP, FIDSA John Rotschafer, PharmD, FCCP |
Learning Objectives
- Describe the role of microbiology and in-vitro susceptibility testing techniques that define methicillin-resistant Staphylococcus aureus (MRSA), vancomycin intermediate Staphylococcus aureus, and vancomycin-resistant Staphylococcus aureus
- Outline the safety and efficacy profiles of current and emerging MRSA treatment options
- Assist in the implementation of antimicrobial stewardship and infection control guidelines and protocols for appropriate medical management of infections caused by MRSA to improve outcomes and minimize the unintended consequences of antimicrobial therapy
UAN 022-999-10-006-L01-P
MEDICATION ERRORS
Preventing Errors with Opiates: Identifying Risk and Choosing Effective Error Reduction Strategies
| Chair |
Matthew Grissinger, RPh, FISMP, FASCP |
Learning Objectives
- Discuss common medication errors that are associated with the dosing and administration of opiates
- Describe methods to assess data and identify risks associated with the opiate-use process in your institution
- Select high-leverage error reduction strategies to reduce the risk associated with the use of opiates
- Identify measures to monitor the success of medication safety initiatives specific to opiates
UAN 022-999-10-007-L05-P
ONCOLOGY
Current and Emerging Multiple Myeloma Management Considerations
| Chair | Presenters |
David G. Frame, PharmD |
Christopher A. Fausel, PharmD, BCPS, BCOP |
Learning Objectives
- Outline multiple myeloma disease background, including incidence and burden of disease
- Describe the current and emerging treatment regimens for patients with multiple myeloma, including first-line, refractory, and maintenance therapy
- Address supportive care issues relevant to health-system pharmacists for patients with multiple myeloma
- Explain the role of gene expression profiling in multiple myeloma management
- Promote the development and implementation of evidence-based treatment protocols for multiple myeloma management
UAN 022-999-10-008-L01-P
RESPIRATORY DISEASE
Reducing the Burden of RSV Infection through Recommended Prevention and Treatment
| Chair | Presenter |
Elizabeth Farrington, PharmD, |
Sherry Luedtke, PharmD |
Learning Objectives
- Describe the incidence, burden, and long-term healthcare implications of respiratory syncytial virus (RSV) infection
- Explain the role of health-system pharmacists in screening infants to identify those at risk for RSV infection
- Outline current methods for the prevention and treatment of RSV
- Apply current guidelines and recommendations for the prevention and treatment of RSV in at-risk infants
- Implement discharge management and communication protocols to ensure continuity of care for RSV prevention and treatment
UAN 022-999-10-009-L01-P
SEDATION
Managing the Pharmacoeconomics of ICU Sedation: Designing and Implementing Protocols for Optimized Care
| Chair | Presenter |
John W. Devlin, PharmD, |
Joseph F. Dasta, MSc, FCCM, FCCP |
Learning Objectives
- Compare and contrast the clinical benefits and limitations of intensive care unit (ICU) sedation therapies
- Outline the spectrum of pharmacoeconomic considerations of ICU sedation therapies, including pharmacy acquisition costs, ventilation and ICU time, and adverse effects of treatment
- Describe the impact of ICU sedation protocols on clinical and economic outcomes
- Design and implement ICU sedation protocols for optimized care
UAN 022-999-10-010-L01-P
Independent Clinical Reviewers: Wendy Cantrell, PharmD, BCPS, BCNSP, CACP, Cardiology Clinical Specialist, University Medical Center of Southern Nevada, University of Southern Nevada College of Pharmacy; Lea S. Eiland, PharmD, BCPS, Associated Clinical Professor of Pharmacy Practice, Auburn University School of Pharmacy; Conan MacDougall, PharmD, MAS, BCPS, Associate Professor of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco, California; Patrick McDonnell, PharmD, Associate Professor of Clinical Pharmacy, Temple University School of Pharmacy; Sachin Shah, PharmD, BCOP, Associate Professor of Pharmacy Practice, Hematology/Oncology Clinical Pharmacist, Texas Tech University Health Sciences Center - School of Pharmacy, VA North Texas Health Care System, Dallas, Texas
Planning Committee
The planning committee comprises Bradley A. Boucher, PharmD, FCCP, FCCM; Wendy Cantrell, PharmD, BCPS, BCNSP, CACP; Joseph F. Dasta, MSc, FCCM, FCCP; John W. Devlin, PharmD, BCPS, FCCM, FCCP; Paul P. Dobesh, PharmD, FCCP, BCPS; Lea S. Eiland, PharmD, BCPS; Elizabeth Farrington, PharmD, FCCP, FCCM, BCPS; Christopher A. Fausel, PharmD, BCPS, BCOP; David G. Frame, PharmD; Randolph V. Fugit, PharmD, BCPS; Matthew Grissinger, RPh, FISMP, FASCP; Sherry Luedtke, PharmD; Conan MacDougall, PharmD, MAS, BCPS; Mark A. Malesker, PharmD; Patrick McDonnell, PharmD; David P. Nicolau, PharmD, FCCP, FIDSA; Robert P. Rapp, PharmD, FCCP; John C. Rotschafer, PharmD, FCCP; Sachin Shah, PharmD, BCOP; Ann K. Wittkwosky, PharmD, CACP, FASHP, FCCP; Chris Dennison, UK HealthCare CECentral, University of Kentucky; and Kristin Dickie, Mary Johnson, Rich Keenan, Nick Lombardi, Randy Robbin, and John Savage, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME and the University of Kentucky College of Pharmacy, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and the University of Kentucky College of Pharmacy to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty has reported the following:
Dr. Boucher: Consultant—Bayer Healthcare, The Medicines Company; Promotional speakers bureau—Bayer Healthcare, ZymoGenetics, Inc
Mr. Dasta: Consultant—Cadence, Cubist, Hospira, Keimar, Inc, Otsuka, The Medicines Company; Promotional speakers bureau—The Medicines Company
Dr. Devlin: Grant/research support—AstraZeneca, Hospira; Consultant—Hospira, Promotional speakers bureau—Takeda
Dr. Dobesh: Consultant—Bristol-Myers Squibb, Ortho McNeil, sanofi-aventis U.S., Promotional speaker’s bureau—sanofi-aventis U.S.
Dr. Eiland: Consultant—McKesson; Promotional speaker’s bureau (spouse)—Astellas Pharma US, Inc, Cubist
Dr. Fausel: Consultant—Bayer Pharmaceuticals; Promotional speakers bureau—Amgen Pharmaceuticals
Dr. Frame: Consultant—Celgene, Millennium Pharmaceuticals, Inc; Promotional speakers bureau—Celgene; Millennium Pharmaceuticals, Inc
Dr. Fugit: Consultant—Astellas Pharma US, Inc, Takeda Pharmaceuticals; Scientific advisor—Novartis Pharmaceuticals, Takeda Pharmaceuticals; Promotional speaker’s bureau—Astellas Pharma US, Inc, Cubist, Takeda Pharmaceuticals, sanofi-aventis, U.S.
Mr. Grissinger: Employee/Officer/Board member (spouse)—Johnson and Johnson
Dr. Malesker: Grant/research support—Bayer Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Inc, Pneuma Pharmaceuticals, Wyeth Pharmaceuticals; Consultant—sanofi-aventis U.S., ZymoGenetics, Inc; Promotional speakers bureau—sanofi-aventis U.S., ZymoGenetics, Inc
Dr. McDonnell: Consultant—Institute for Safe Medication Practices
Dr. Nicolau: Grant/research support—Astellas Pharma US, Inc, AstraZeneca, Cubist, Merck and Co., Inc, Ortho-McNeil, Pfizer, Inc; Consultant— Astellas Pharma US, Inc, AstraZeneca, Cubist, Merck and Co., Inc, Ortho-McNeil, Pfizer, Inc; Scientific advisor— Astellas Pharma US, Inc, AstraZeneca, Cubist, Merck and Co., Inc, Ortho-McNeil, Pfizer, Inc; Promotional speakers bureau— Astellas Pharma US, Inc, AstraZeneca, Cubist, Merck and Co., Inc, Ortho-McNeil, Pfizer, Inc;
Dr. Rapp: Consultant—Astellas Pharma US, Inc, Ortho-McNeil, Pfizer, Inc; Scientific advisor—Astellas Pharma US, Inc, Ortho-McNeil, Pfizer, Inc; Promotional speakers bureau—Astellas Pharma US, Inc, Ortho-McNeil, Pfizer, Inc
Dr. Rotschafer: Grant/research support—AstraZeneca, Ortho-McNeil; Consultant—Astellas Pharma US, Inc, Bayer Pharmaceuticals, Cubist, Optimer, Ortho-McNeil, Regions Hospital, Theravance, Trius; Promotional speakers bureau—Astellas Pharma US, Inc, Cubist, Ortho-McNeil, Pfizer, Inc
Dr. Shah: Advisory board—Celgene
Dr. Cantrell, Dr. Farrington, Dr. Luedtke, Dr. MacDougall, and Dr. Wittkowsky disclosed no relevant financial relationships with any commercial interests.
Mr. Dennison, Ms. Dickie, Ms. Johnson, Mr. Keenan, Mr. Lombardi, Mr. Robbin, and Mr. Savage have disclosed no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
Off-label/unapproved uses of drugs and/or devices will be disclosed in the activity materials.
Privacy Policy
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2010 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic, or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Grant Support
Supported by educational grants from MedImmune, Millennium Pharmaceuticals, Inc, sanofi-aventis U.S., and ZymoGenetics, Inc.
Representatives of the granting organization may not register on behalf of participants.
Click here to register
